HRZE Tablet Dosing by Weight
For adults with drug-susceptible tuberculosis, administer fixed-dose combination (FDC) tablets containing rifampicin 120mg/isoniazid 50mg/pyrazinamide 300mg/ethambutol 275mg based on weight bands: 4 tablets daily for patients <45kg, 5 tablets for 45-54kg, and 6 tablets for ≥55kg during the 2-month intensive phase. 1
Weight-Based Dosing Algorithm
Adults - Daily Regimen (Intensive Phase)
Using Rifater-type FDC (RIF 120mg/INH 50mg/PZA 300mg per tablet):
- ≤44 kg: 4 tablets daily
- 45-54 kg: 5 tablets daily
- ≥55 kg: 6 tablets daily
Note: For patients >90kg, additional pyrazinamide tablets may be needed to achieve adequate dosing 1
Children (3 months to 16 years) - Daily Regimen
Using pediatric dispersible FDC (RIF 75mg/INH 50mg/PZA 150mg):
- <8 kg: 1 tablet daily
- 8-12 kg: 2 tablets daily
- 12-16 kg: 3 tablets daily
- 16-25 kg: 4 tablets daily
For optimal rifampicin exposure, consider revised FDC formulation (RIF 120mg/INH 35mg/PZA 130mg):
- <6 kg: 1 tablet daily
- 6-13 kg: 2 tablets daily
- 13-20 kg: 3 tablets daily
- 20-25 kg: 4 tablets daily 2
Alternative: Individual Drug Dosing (mg/kg/day)
If FDC tablets unavailable, dose individual drugs daily as:
Adults:
- Isoniazid: 5 mg/kg (max 300mg)
- Rifampicin: 10 mg/kg (max 600mg)
- Pyrazinamide: 15-30 mg/kg (max 2g)
- Ethambutol: 15-25 mg/kg (max 2.5g) 1, 3, 4
Children:
- Isoniazid: 10-15 mg/kg (max 300mg)
- Rifampicin: 10-20 mg/kg (max 600mg)
- Pyrazinamide: 15-30 mg/kg (max 2g)
- Ethambutol: 15-25 mg/kg (max 2.5g) 5
Intermittent Dosing (Twice Weekly - DOT Only)
Adults:
- Isoniazid: 15 mg/kg (max 900mg)
- Rifampicin: 10 mg/kg (max 600mg)
- Pyrazinamide: 50-70 mg/kg
- Ethambutol: 50 mg/kg 1
Children:
- Isoniazid: 20-30 mg/kg (max 900mg)
- Rifampicin: 10-20 mg/kg (max 600mg)
- Pyrazinamide: 50-70 mg/kg 5
Critical Implementation Points
Fixed-Dose Combinations Are Preferred
FDC tablets should be used whenever possible to prevent inadvertent monotherapy and reduce acquired drug resistance, particularly when directly observed therapy (DOT) is not feasible 1. The bioavailability of drugs in FDC formulations is equivalent to individual drug administration 6, 7.
Weight Band Considerations
The British Thoracic Society uses a 50kg cutoff for rifampicin dosing: 450mg for <50kg, 600mg for ≥50kg 8. However, the American guidelines provide more granular weight bands that better optimize drug exposure 1.
Pediatric Dosing Challenges
Current WHO-recommended pediatric FDC formulations result in suboptimal rifampicin exposures, particularly in children <55kg, with exposures up to 50% lower than adults 2. The revised FDC formulation (RIF 120mg/INH 35mg/PZA 130mg) addresses this deficiency while avoiding excessive isoniazid and pyrazinamide exposure.
Special Populations
HIV co-infection: Same weight-based dosing applies, though longer treatment duration may be required. Monitor for drug interactions with antiretrovirals 9, 5.
Hepatic disease: Use individual drug formulations initially rather than FDC to allow selective drug withdrawal if hepatotoxicity develops 1.
Renal insufficiency: Ethambutol requires dose adjustment when creatinine clearance <70 mL/min; administer 15-20 mg/kg three times weekly after dialysis 1.
Common Pitfalls
- Underdosing in lower weight bands: Patients <55kg frequently receive inadequate rifampicin with standard FDC dosing
- Overdosing pyrazinamide in heavy patients: Those >90kg require careful calculation to avoid exceeding 2g daily maximum 3
- Ethambutol in young children: Some clinicians exclude ethambutol in children who cannot report visual changes, though most experts include it in the intensive phase 10